Pravin Dugel, MD, managing partner, Retinal Consultants of Arizona,delivers a frank overview of the pipeline of experimental retinal drugs. The next year could be critical for retinal disease as combination therapies and other products push through late-stage clinical trials. What technologies show the most promise? What advances have surprised even him?
STAY UP TO DATE WITH OIS
Get the Latest News, Podcasts and Videos.